Strategies Wealth Advisors’s Contineum Therapeutics CTNM Stock Holding History

Strategies Wealth Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$820K	Hold	50,000	–	–	0.07%	90
2026 Q1	$653K	Hold	50,000	–	–	0.07%	83
2025 Q4	$572K	Hold	50,000	–	–	0.06%	87
2025 Q3	$588K	Hold	50,000	–	–	0.06%	93
2025 Q2	$199K	Buy	50,000 +25,000	+100%	+$109K	0.02%	178
2025 Q1	$175K	Hold	25,000	–	–	0.02%	171
2024 Q4	$206K	Buy	+25,000	New	+$396K	0.03%	121

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Strategies Wealth Advisors's CTNM Position: Q2 2026 in Review

Strategies Wealth Advisors held its Contineum Therapeutics (CTNM) position steady in Q2 2026 at 50,000 shares worth $820K. The position accounts for 0.07% of the portfolio, ranked #90.

Strategies Wealth Advisors first reported a position in CTNM in Q4 2024 and has held it in 7 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

Strategies Wealth Advisors held 50,000 shares of Contineum Therapeutics worth $820K as of Q2 2026.
Strategies Wealth Advisors left its Contineum Therapeutics share count unchanged in Q2 2026.
Contineum Therapeutics made up 0.07% of Strategies Wealth Advisors's portfolio in Q2 2026, its #90 holding.
Strategies Wealth Advisors first reported a position in Contineum Therapeutics in Q4 2024 and has held it in 7 quarters since.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Strategies Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.